Manager TitleAgeSince
President 63 27/05/2010
Director TitleAgeSince
Director/Board Member 63 26/03/2010
Director/Board Member 85 01/06/2011
Director/Board Member 79 09/05/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
+0.24%-1.54%+52.85%+60.31% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+4.81%+3.86%+38.43%-4.18% 19.36B
-1.14%+0.03%+31.67%-31.21% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+5.47%+1.79%+35.86%+657.20% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.18%-2.62%+42.72%+181.13% 25.95B
Weighted average by Cap. -1.12%-2.36%+40.96%+139.47%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-